Along with their unique beneficial features such as the production of abundant pro-inflammatory cytokines, including IFN-γ and TNF-α, MHC-independent recognition of antigens, direct lysis of tumor cells, antibody-dependent cellular cytotoxicity (ADCC), and antigen presentation capacity [46], γδ T cells are proposed to constitute a promising target in cancer immunotherapy. This evidence concerns the gene HLA-C and neoplasm.